<DOC>
	<DOCNO>NCT00070551</DOCNO>
	<brief_summary>This phase I trial study side effect best dose GTI-2040 high-dose cytarabine treat patient refractory relapse acute myeloid leukemia . GTI-2040 may stop growth cancer cell block enzymes necessary cancer cell growth . Drugs use chemotherapy , cytarabine , use different way stop cancer cell divide stop grow die . Giving GTI-2040 together cytarabine may kill cancer cell .</brief_summary>
	<brief_title>GTI-2040 High-Dose Cytarabine Treating Patients With Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose GTI-2040 high-dose cytarabine patient relapse refractory acute myeloid leukemia . SECONDARY OBJECTIVES : I . Determine therapeutic response patient treat regimen . II . Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation study . Patients stratify accord age ( age 60 v age 60 ) . Patients assign 1 2 stratum . Stratum I ( age 60 ) : Patients receive GTI-2040 IV continuously day 1-6 high-dose cytarabine IV 2 hour twice daily day 2 , 4 , 6 . Stratum II ( age 60 ) : Patients receive GTI-2040 IV continuously day 1-6 high-dose cytarabine IV 4 hour daily day 2-6 . In stratum , treatment continue absence unacceptable toxicity . Cohorts 3-6 patient per stratum receive escalate dos GTI-2040 high-dose cytarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 6-51patients accrue study within 2-16 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Histologically confirm acute myeloid leukemia accord WHO classification Relapsed refractory disease , meet 1 follow criterion : Unresponsive initial treatment Recurrent disease treatment prior conventional highdose chemotherapy without stem cell support CNS involvement allow provide residual leukemic cell detect cerebrospinal fluid intrathecal radiation chemotherapy Performance status ECOG 02 At least 4 week Bilirubin great 2 time upper limit normal* ( ULN ) ( unless due Gilbert 's syndrome ) AST ALT great 3 time ULN* Creatinine great 1.5 mg/dL* No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Resting ejection fraction least 50 % * Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergy study medication No ongoing active infection require IV antibiotic No concurrent uncontrolled illness No serious medical psychiatric illness would preclude give informed consent More 4 week since prior chemotherapy ( except hydroxyurea ) ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy No concurrent hormonal therapy except steroid adrenal failure hormone nondiseaserelated condition ( e.g. , insulin diabetes ) More 4 week since prior radiotherapy No concurrent palliative radiotherapy Prior therapy antisense oligonucleotides allow provide toxic effect experience directly attributable antisense agents No concurrent investigational agent No concurrent anticancer therapy No concurrent chronic systemic anticoagulant therapy medical condition ( e.g. , prior deep vein thrombosis atrial fibrillation ) Concurrent heparin maintain central line patency ( i.e. , catheter flush ) allow No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>